Mikhail Byakhov

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

Luca Gianni, José Baselga, W. Eiermann et al. · Journal of Clinical Oncology · 2009 · 216 citations · Full text

Medicine, Oncology, Pharmacology +17

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

Luca Gianni, José Baselga, W. Eiermann et al. · Clinical Cancer Research · 2005 · 165 citations

Medicine, Oncology, Pharmacology +15

Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models

Ilya Tsimafeyeu, John Ludes-Meyers, Frits Daeyaert et al. · European Journal of Cancer · 2016 · 39 citations

Medicine, Oncology, Pharmacology +7

Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

Alexandra Tyulyandina, Daniel Harrison, Wei Yin et al. · Investigational New Drugs · 2016 · 24 citations

Medicine, Oncology, Pharmacology +14

Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)

Lee Hartner, Lee S. Rosen, Martee L. Hensley et al. · Journal of Clinical Oncology · 2007 · 23 citations

Medicine, Oncology, Pharmacology +17